# MPM Capital

> MPM Capital is a VC fund in Cambridge backing Biotechnology and Health Care. See 232 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 232
- Last investment: Dec 2025
- Lead investor: 35%
- Fund size: $850M
- Last fund: Oct 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/mpm-capital
- X (Twitter): http://twitter.com/mpmcapital
- Website: http://www.mpmcapital.com

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

## Contacts

5 contacts available for MPM Capital. Shizune tracks 18 team members at MPM Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mpm-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $10M–$80M |
| Series B | $20M–$116M |
| Series C | $12M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 112 | 48% |
| Health Care | 73 | 31% |
| Pharmaceutical | 46 | 20% |
| Therapeutics | 45 | 19% |
| Medical | 36 | 16% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 52 | 22% |
| Series A | 51 | 22% |
| Series C | 39 | 17% |
| Funding Round | 20 | 9% |
| Series D | 17 | 7% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 117 | 50% |
| Canada | 3 | 1% |
| United Kingdom | 3 | 1% |
| Germany | 2 | 1% |
| Italy | 1 | 0% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David P. Ryan | Medical and Scientific Advisor | 1 | https://shizune.co/investors/profile/david-p-ryan |
| Detlev Biniszkiewicz | Executive Partner | 3 | https://shizune.co/investors/profile/detlev-biniszkiewicz |
| Uciane Scarlett | Principal | 4 | https://shizune.co/investors/profile/uciane-scarlett |
| Ansbert Gadicke | Managing Director and Co-Founder | 12 | https://shizune.co/investors/profile/ansbert-k-gadicke |
| Bard Geesaman | Managing Director | 5 | https://shizune.co/investors/profile/bard-geesaman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Protego Biopharma | Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M | Series B | Dec 01, 2025 |  |
| Reunion Neuroscience | Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M | Series A | Sep 16, 2025 |  |
| Umoja Biopharma | Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer. | $100M | Series C | Jan 14, 2025 |  |
| āshibio | āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course. | $40M | Series A | Jun 20, 2024 |  |
| Frontier Medicines | Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery anddevelopment, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases. | $80M | Series C | Feb 22, 2024 |  |
| Firefly Bio | Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders. | $94M | Series A | Feb 15, 2024 |  |
| NextPoint Therapeutics | NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $42.5M | Series B | Feb 14, 2024 |  |
| AstronauTx | AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes. | $58.7M | Series A | Oct 08, 2023 |  |
| Deka Biosciences | Early stage biotechnology start-up developing next generation cytokine therapeutics | $20M | Series B | Sep 28, 2023 |  |
| Deka Biosciences | Early stage biotechnology start-up developing next generation cytokine therapeutics | $20M | Series B | Sep 28, 2023 |  |

10 of 232 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 19 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 17 deals together
- [F2 Ventures](https://shizune.co/investors/profile/f2-ventures) — VC Fund, 16 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 15 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 14 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 14 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)

## FAQ

### What does MPM Capital invest in?

MPM Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 232 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is MPM Capital's check size?

MPM Capital typically joins rounds of $10M–$80M at Series A, $20M–$116M at Series B and $12M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds MPM Capital participates in.

### How do I contact MPM Capital?

Public channels for MPM Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at MPM Capital?

The team at MPM Capital includes David P. Ryan (Medical and Scientific Advisor), Detlev Biniszkiewicz (Executive Partner) and Uciane Scarlett (Principal), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co